Management of ascites in cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 11-20

  Wong, Florence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ascites; Diuretics; Large volume paracentesis; Portal hypertension; Renal sodium retention; TIPS

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; AMILORIDE; CANRENOATE POTASSIUM; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; MIDODRINE; SODIUM; SPIRONOLACTONE; VASOCONSTRICTOR AGENT;

ARTICLE; ASCITES; DIETITIAN; DIURESIS; DIURETIC THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; IMPLANT; KIDNEY FAILURE; LARGE VOLUME PARACENTESIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MEAN ARTERIAL PRESSURE; NUTRITIONAL REQUIREMENT; PARACENTESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SODIUM ABSORPTION; SODIUM BALANCE; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM RETENTION; SODIUM URINE LEVEL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; WEIGHT REDUCTION;

EID: 84155174993     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06925.x     Document Type: Article

References (69)

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44: 217-31.
2. Planas R, Montoliu S, Balleste B etal. Natural history of patients hospitalized for management of cirrhotic ascites. Clin. Gastroenterol. Hepatol. 2006; 4: 1385-94.
3. Cardenas A, Arroyo V. Management of ascites and hydrothorax. Best Pract. Res. Clin. Gastroenterol. 2007; 21: 55-75.
4. Leung W, Wong F. Medical management of ascites. Expert Opin. Pharmacother. 2011; 12: 1269-83.
5. Moore KP, Wong F, Gines P etal. The management of ascites-report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
6. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.
7. Angeli P, Della Pria M, De Bei E etal. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994; 19: 72-9.
8. Bolondi L, Piscaglia A, Gatta A etal., DOC (Decrease Of Complications in cirrhosis) Study Group. Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis. Clin. Gastroenterol. Hepatol. 2006; 4: 1395-402.
9. Santos J, Planas R, Pardo A etal. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J. Hepatol. 2003; 39: 187-92.
10. Angeli P, Fasolato S, Mazza E etal. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010; 59: 98-104.
11. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N. Engl. J. Med. 1970; 282: 1391-6.
12. Pinto-Marques P, Vieira A. Urinary sodium/potassium ratio on random sample as a useful tool to assess diuretic-induced natriuresis on chronic liver disease-associated ascites. Am. J. Gastroenterol. 2007; 102: 212-13.
13. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007; 4: 43-51.
14. Fernández J, Monteagudo J, Bargallo X etal. A Randomized unblinded pilot study comparing albumin versus hydroethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-34.
15. Guevara M, Arroyo V. Hepatorenal syndrome. Expert Opin. Pharmacother. 2011; 12: 1405-17.
16. Cárdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract. Res. Clin. Endocrinol. Metab. 2003; 17: 607-22.
17. Gentilini P, Casini-Raggi V, Di Fiore G etal. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol. 1999; 30: 639-45.
18. Romanelli RG, La Villa G, Barletta G etal. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J. Gastroenterol. 2006; 12: 1403-7.
19. Salerno F, Guevara M, Bernardi M etal. Refractory ascites, pathogenesis, definition, and therapy of a severe complication in cirrhotic patients. Liver Int. 2010; 30: 937-47.
20. Gines P, Arroyo V, Quintero E etal. Comparison of paracentesis and diuretics in the treatment of cirrhosis with tense ascites: results of a randomized study. Gastroenterology 1987; 93: 234-41.
21. Salerno F, Badalamenti S, Incerti P etal. Repeated paracentesis and i.v. albumin infusion to treat "tense" ascites in ascitic patients: a safe alternative therapy. J. Hepatol. 1987; 5: 102-8.
22. Pinto PC, Amerian J, Reynolds TB. Large volume paracentesis in non-edematous patients with tense ascites: its effect on intravascular volume. Hepatology 1988; 8: 207-10.
23. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and the effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
24. Peltekian K, Wong F, Liu P, Allidina Y, Sherman M, Blendis LM. The effect of large volume paracentesis on total central blood volume, systemic and renal hemodynamics and renal sodium handling in cirrhosis. Am. J. Gastroenterol. 1997; 92: 394-9.
25. Sola-Vera J, Minana J, Ricart E etal. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53.
26. Gines P, Tito L, Arroyo V etal. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
27. Moreau R, Asselah T, Condat B etal. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-4.
28. Gines A, Fernandez-Esparrach G, Monescillo A etal. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
29. Panos MZ, Moore K, Vlavianos P etal. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology 1990; 11: 662-7.
30. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707-13.
31. Moreau R, Valla DC, Durand-Zaleski I etal. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomized controlled pilot trial. Liver Int. 2006; 26: 46-54.
32. James PD, Oosterveld L, Wong F. Circulatory dysfunction after large volume paracentesis in patients with cirrhosis and ascites. (Abstract). Hepatology 2009; 50 (Suppl. 4): 476A.
33. Thomsen TW, Shaffer RW, White B, Setnik GS. Videos in clinical medicine: paracentesis. N. Engl. J. Med. 2006; 355: e21.
34. Wong F, Sniderman K, Liu P, Blendis LM. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 112: 899-907.
35. Wong W, Liu P, Blendis LM, Wong F. Renal sodium handling during long-term follow-up and the effect of sodium loading in cirrhotic patients treated with TIPS for refractory ascites. Am. J. Med. 1999; 106: 315-22.
36. Wong F. Cirrhotic cardiomyopathy. Hepatol. Int. 2009; 3: 294-304.
37. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am. J. Gastroenterol. 2009; 104: 2458-66.
38. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am. J. Gastroenterol. 2001; 96: 2442-7.
39. Lebrec D, Giuily N, Hadenque A etal. Transjugular intrahepatic portosystemic shunt: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J. Hepatol. 1996; 25: 135-44.
40. Rossle M, Ochs A, Gulberg V etal. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N. Engl. J. Med. 2000; 342: 1701-7.
41. Sanyal A, Gennings C, Reddy KR etal., and the North American Study for Treatment of Refractory Ascites. A randomized controlled study of TIPS versus large volume paracentesis in the treatment of refractory ascites. Gastroenterology 2003; 124: 634-43.
42. Gines P, Uriz J, Calahorra B etal. Transjugular intrahepatic portosystemic shunt versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis. A multicenter randomized comparative study. Gastroenterology 2002; 123: 1839-47.
43. Salerno F, Merli M, Riggio O etal. Randomized controlled study of TIPS vs. paracentesis with albumin in cirrhosis with refractory ascites. Hepatology 2004; 40: 629-35.
44. D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 1282-93.
45. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J. Clin. Gastroenterol. 2007; 41 (Suppl. 3): S344-51.
46. Sanyal AJ, Freedman AM, Luketic VA etal. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889-98.
47. Barrio J, Ripoll C, Banares R etal. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. Eur. J. Radiol. 2005; 55: 120-4.
48. Riggio O, Angeloni S, Salvatori FM etal. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene -covered stent grafts. Am. J. Gastroenterol. 2008; 103: 2738-46.
49. Angermayr B, Cejna M, Koenig F etal., Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003; 38: 1043-50.
50. Jung HS, Kalva SP, Greenfield AJ etal. TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent grafts. J. Vasc. Interv. Radiol. 2009; 20: 180-5.
51. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites, a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-34.
52. Kamath PS, Wiesner RH, Malinchoc M etal. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
53. Heuman DM, Abou-Assi SG, Habib A etal. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-10.
54. Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM. Ascites improves upon serum sodium plus Model for End-Stage Liver Disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment. Pharmacol. Ther. 2009; 30: 741-8.
55. Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low Model for End-Stage Liver Disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl. 2011; 17: 129-36.
56. Gotthardt D, Weiss KH, Baumgartner M etal. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol. 2009; 9: 72.
57. Wong F, Pantea L, Sniderman K. The use of midodrine, octreotide and transjugular intrahepatic portosystemic stent shunt in the treatment of cirrhotic patients with ascites and renal dysfunction including hepatorenal syndrome. Hepatology 2004; 40: 55-64.
58. Angeli P, Volpin R, Piovan D etal. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-43.
59. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J. Hepatol. 2007; 46: 213-21.
60. Misra VL, Vuppalanchi R, Jones D etal. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment. Pharmacol. Ther. 2010; 32: 1044-50.
61. Tandon P, Tsuyuki RT, Mitchell L etal. The effect of 1month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009; 29: 169-74.
62. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-71.
63. Kalambokis GN, Pappas K, Baltayiannis G, Katsanou A, Tsianos EV. Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scand. J. Gastroenterol. 2010; 45: 1509-15.
64. Wong F, Blei A, Blendis LM, Robertson G, Thuluvath PJ, the North American VPA-985 Study Group. The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: a multi-center randomized placebo controlled trial. Hepatology 2003; 37: 182-91.
65. 2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006; 355: 2099-112.
66. 2 receptor antagonist, on ascites and serum sodium concentration in patients with cirrhosis and hyponatremia. Hepatology 2008; 48: 204-13.
67. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M. Ginès P, for the Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2011 (in press).
68. V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites. J. Hepatol. 2009; 50 (Suppl. 1): S76.
69. Okita K, Sakaida I, Okada M etal. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J. Gastroenterol. 2010; 45: 979-87.